Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
Thromboxane is a bioactive lipid produced by platelets that plays a crucial role in hemostasis, primarily by promoting blood clotting and causing the constriction of blood vessels. There are two main forms of thromboxane: Thromboxane A2, which is biologically active but highly unstable, and Thromboxane B2, which is an inactive metabolite of Thromboxane A2. The measurement of thromboxane metabolites, particularly Thromboxane B2, in urine is significant for evaluating various pathological conditions. The excretion of these metabolites can provide valuable insights into several disease states, including liver disease, inflammatory lung diseases, and organ rejection in transplant patients, among other medical conditions. For accurate assessment, a 24-hour urine sample is typically collected, allowing for comprehensive testing of thromboxane B2 metabolites. Additionally, the specimen may also be analyzed for the presence of Thromboxane A2, further enhancing the diagnostic utility of this test.
© Copyright 2026 Coding Ahead. All rights reserved.
Thromboxane metabolite testing is indicated for the evaluation of various medical conditions that may affect platelet function and vascular health. The following are specific indications for performing this test:
The procedure for testing thromboxane metabolites in urine involves several key steps to ensure accurate results. The first step is the collection of a 24-hour urine sample. This is crucial as it provides a comprehensive overview of thromboxane B2 metabolites excreted over a full day, minimizing variability that could arise from single urine samples. Patients are typically instructed to collect all urine produced over a 24-hour period, ensuring that the sample is stored properly to maintain its integrity. After collection, the urine specimen is sent to a laboratory for analysis. In the laboratory, the sample undergoes testing to detect the presence of thromboxane B2 metabolites. Additionally, if indicated, the laboratory may also test for thromboxane A2. The results of these tests can then be interpreted in the context of the patient's clinical condition, aiding in the diagnosis and management of the underlying health issues.
After the urine sample has been collected and sent for analysis, there are generally no specific post-procedure care requirements for the patient. However, it is important for healthcare providers to communicate the results of the test to the patient once they are available. Depending on the findings, further diagnostic evaluations or treatment plans may be necessary. Patients should be advised to follow up with their healthcare provider to discuss the implications of the test results and any subsequent steps that may be required based on their individual health status.
| Short Descr | THROMBOXANE URINE | Medium Descr | THROMBOXANE METABOLITE W/WO THROMBOXANE URINE | Long Descr | Thromboxane metabolite(s), including thromboxane if performed, urine | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 233 - Laboratory - Chemistry and Hematology |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GA | Waiver of liability statement issued as required by payer policy, individual case | GW | Service not related to the hospice patient's terminal condition | GZ | Item or service expected to be denied as not reasonable and necessary |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2011-01-01 | Changed | Short description changed. |
| 2010-01-01 | Added | - |
Get instant expert-level medical coding assistance.